Issue: May 2011
May 01, 2011
1 min read
Save

SYNTAX: Angina slightly improved in CABG vs. PCI patients

Cohen D. N Engl J Med. 2011;364:1016-1026.

Issue: May 2011
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

A new quality-of-life substudy of the SYNTAX trial has shown that among patients with three-vessel or left main coronary artery disease, there was greater angina relief in those treated with CABG compared with percutaneous coronary intervention at 6 and 12 months.

In the Synergy Between PCI With Taxus and Cardiac Surgery (SYNTAX) trial, a group of investigators allocated 1,800 patients (mean age, 65 years) with three-vessel disease or left main CAD to be treated with either PCI with paclitaxel-eluting stents (Taxus, Boston Scientific; n=903) or CABG (n=897). Using the Seattle Angina Questionnaire (SAQ) and the Medical Outcomes Study 36-Item Short-Form Health Survey, they then assessed health-related quality of life at four intervals: baseline, 1 month, 6 months and 12 months.

At 6 and 12 months vs. baseline, both groups had significantly higher scores with both surveys, indicating better health status. A greater improvement on the angina-frequency subscale of the SAQ, however, was reported in the CABG group at 6 (P=.04) and 12 (P=.03) months, yet the differences between groups were small and did not reach 2 points for either periods. Although freedom from angina assessed by SAQ was similar for both procedures at 1 and 6 months, there was a trend toward an improvement in the CABG group at 1 year (P=.05).

In the conclusion of the study, the researchers said the symptomatic benefits of CABG were counterbalanced by the more rapid recovery and improved short-term health status achieved with PCI.

The study was funded by Boston Scientific. Previous coverage of the SYNTAX trial can be accessed here.

Twitter Follow CardiologyToday.com on Twitter.